Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Treatment satisfaction, adherence and behavioral assessment in patients de - escalating from natalizumab to interferon beta.
Altered Expression of Oligodendrocyte and Neuronal Marker Genes Predicts the Clinical Onset of Autoimmune Encephalomyelitis and Indicates the Effectiveness of Multiple Sclerosis-Directed Therapeutics.
Teva and Active Biotech remain committed to the development of NERVENTRA® (laquinimod) for multiple sclerosis following the negative opinion from the EMA's CHMP
Better Prognosis of Multiple Sclerosis in Patients Who Experienced a Full-Term Pregnancy.
Genzyme submits applications to FDA and EMA for approval of LEMTRADA™ (alemtuzumab) for multiple sclerosis
Translating Fatigue to Human Performance.
Evaluating the response to glatiramer acetate in relapsing-remitting multiple sclerosis (RRMS) patients.
Santhera Announces Successful Outcome of Phase III Study with Catena®/Raxone® in Duchenne Muscular Dystrophy
The effect of oral immunomodulatory therapy on treatment uptake and persistence in multiple sclerosis.
Rituximab in paediatric onset multiple sclerosis: a case series.
Background information on multiple sclerosis patients stopping ongoing immunomodulatory therapy: a multicenter study in a community-based environment.
Current and future disease-modifying therapies in multiple sclerosis.
TGN1412: From Discovery to Disaster.
New Tysabri data reaffirm substantial efficacy in treatment of people with MS and demonstrate stability of anti-JCV antibody status
Elevation of Sema4A Implicates Th Cell Skewing and the Efficacy of IFN-β Therapy in Multiple Sclerosis.
The Clinical Meaning of Walking Speed as Measured by the Timed 25-Foot Walk in Patients With Multiple Sclerosis.
[The first experience of the use the Russian Β-interferon-1b biosimilar (infibeta) in the daily practice of the Moscow Center of Multiple Sclerosis.]
FDA denies Teva Copaxone generic trials petition
Subcutaneous administration of alemtuzumab in patients with highly active multiple sclerosis.
Glatiramer acetate during early pregnancy: A prospective cohort study.
Improvement in disability after alemtuzumab treatment of multiple sclerosis is associated with neuroprotective autoimmunity.
Prospective Observational Long-term Safety Registry of Multiple Sclerosis Patients Who Have Participated in Cladribine Clinical Trials
[Neuromyelitis optica following thymectomy with severe spinal cord atrophy after frequent relapses for 30 years].
A meta-analysis of whole genome linkage screens in multiple sclerosis.
Opioid growth factor and low-dose naltrexone impair central nervous system infiltration by CD4 + T lymphocytes in established experimental autoimmune encephalomyelitis, a model of multiple sclerosis.

Pages